Progress in the development of KRAS inhibitors is particularly crucial because successful implementation of KRAS‐targeted therapy could revolutionize treatment outcomes, especially considering the high malignancy of pancreatic cancers. Here, KRAS is linked to familial pancreatic carcinoma.